カテゴリ： GlobalData, アメリカ, 企業調査

Ocular Therapeutix Inc (OCUL)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Ocular Therapeutix Inc (OCUL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8104
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：65
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Ocular Therapeutix Inc (Ocular), formerly I-Therapeutix Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for diseases using hydrogel platform technology. The company’s products include DEXTENZA, sustained release travoprost and posterior segment injections. Its hydrogel technology uses polyethylene glycol to create ophthalmic sustained drug delivery systems. Ocular’s hydrogel provides containment, localization and protection from inflammatory response, and a material for sustained delivery of drugs to the eye. The company also provides ReSure Sealant, a ocular sealant proven in clinical trial to be safe in sealing clear corneal incisions following cataract surgery. Its products are used for the treatment of glaucoma and ocular hypertension, post-operative inflammation, allergic conjunctivitis, dry eye and retinal diseases. Ocular is headquartered in Bedford, Massachusetts, the US.

Ocular Therapeutix Inc (OCUL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ocular Therapeutix Inc, Medical Devices Deals, 2012 to YTD 2018 10
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Ocular Therapeutix Raises US$8.5 Million In Series E Venture Financing 12
Ocular Therapeutix Raises US$24 Million In Extended Series D Financing 13
Partnerships 15
Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 15
Equity Offering 17
Ocular Therapeutix Raises USD37.3 Million in Public Offering of Shares 17
Ocular Therapeutix Prices Public Offering of Shares for USD25 Million 19
Ocular Therapeutix Raises USD101.2 Million in Public Offering of Shares 21
Ocular Therapeutix Completes Exercise of Underwriter’s Over Allotment Option for IPO for USD75 Million 23
Ocular Therapeutix Inc – Key Competitors 25
Ocular Therapeutix Inc – Key Employees 26
Ocular Therapeutix Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 07, 2018: Ocular Therapeutix announces second quarter 2018 financial results 28
Mar 08, 2018: Ocular Therapeutix Reports Fourth Quarter and Year End 2017 Financial Results and Business Update 29
Nov 07, 2017: Ocular Therapeutix Reports Third Quarter 2017 Financial Results and Provides Corporate Update 31
Aug 08, 2017: Ocular Therapeutix Reports Second Quarter 2017 Financial Results and Provides Corporate Update 33
Aug 03, 2017: Ocular Therapeutix Appoints Daniel Bollag, Ph.D., as Senior Vice President, Regulatory Affairs, Pharmacovigilance and Quality 35
Aug 01, 2017: Ocular Therapeutix Announces Antony Mattessich Assumes Role as Chief Executive Officer 36
May 05, 2017: Ocular Therapeutix Reports First Quarter 2017 Financial Results 37
Corporate Communications 39
Sep 08, 2017: Ocular Therapeutix Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer 39
Jun 26, 2017: Ocular Therapeutix Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 40
Jun 22, 2017: Ocular Therapeutix Announces Executive Transition Plans 41
Apr 06, 2017: Ocular Therapeutix Appoints George Migausky as Interim Chief Financial Officer 42
Mar 10, 2017: Ocular Therapeutix Reports Fourth Quarter and Full Year 2016 Financial Results 43
Product News 45
12/22/2017: Ocular Therapeutix Provides Legal Update 45
05/02/2017: Ocular Therapeutix Announces Data on OTX-TKI at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 46
01/08/2018: Ocular Therapeutix Announces Kevin Hanley as Senior Vice President, Technical Operations and Naymisha Patel as Vice President of Quality 47
Product Approvals 48
Jul 12, 2017: OCULAR THERAPEUTIX INVESTOR ALERT: Legal Investigation Continues After FDA Denies Dextenza New Drug Application 48
Jul 11, 2017: Ocular Therapeutix Receives Complete Response Letter from FDA for DEXTENZA NDA 49
Jul 10, 2017: Ocular Therapeutix Submits Amendment to Potentially Extend Review for DEXTENZA New Drug Application 50
Feb 22, 2017: Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for DEXTENZA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery 51
Jan 23, 2017: Ocular Therapeutix Resubmits NDA for DEXTENZA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery 52
Clinical Trials 53
Apr 09, 2018: Ocular Therapeutix to Present Data at the American Society of Cataract and Refractive Surgery Symposium 53
May 11, 2017: Ocular Therapeutix Presented Phase 3 Data for DEXTENZA at the Association for Research in Vision and Ophthalmology Annual Meeting 54
May 09, 2017: Ocular Therapeutix Presents Preclinical Data on Pharmacokinetics, Efficacy and Tolerability of Sustained Release Intravitreal Tyrosine Kinase Inhibitor Hydrogel Depot (OTX-TKI) at the ARVO Annual Meeting 56
May 08, 2017: Ocular Therapeutix Presents Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium 58
May 02, 2017: Ocular Therapeutix to Present Data on DEXTENZA at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 59
May 02, 2017: Ocular Therapeutix to Present Data on OTX-TP (travoprost insert) at the Association for Research in Vision and Ophthalmology Annual Meeting 60
Apr 24, 2017: Ocular Therapeutix to Present Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium 61
Mar 15, 2017: New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix DEXTENZA Following Cataract Surgery 63
Jan 04, 2017: Ocular Therapeutix Announces Additional Successful Results for Phase 3 Clinical Trial of DEXTENZA 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ocular Therapeutix Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Ocular Therapeutix Inc, Medical Devices Deals, 2012 to YTD 2018 10
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ocular Therapeutix Raises US$8.5 Million In Series E Venture Financing 12
Ocular Therapeutix Raises US$24 Million In Extended Series D Financing 13
Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 15
Ocular Therapeutix Raises USD37.3 Million in Public Offering of Shares 17
Ocular Therapeutix Prices Public Offering of Shares for USD25 Million 19
Ocular Therapeutix Raises USD101.2 Million in Public Offering of Shares 21
Ocular Therapeutix Completes Exercise of Underwriter's Over Allotment Option for IPO for USD75 Million 23
Ocular Therapeutix Inc, Key Competitors 25
Ocular Therapeutix Inc, Key Employees 26
Ocular Therapeutix Inc, Other Locations 27

List of Figures
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ocular Therapeutix Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Ocular Therapeutix Inc (OCUL)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Royal BAM Group nv：企業の戦略・SWOT・財務分析
    Royal BAM Group nv - Strategy, SWOT and Corporate Finance Report Summary Royal BAM Group nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Valeritas Inc：医療機器：M&Aディール及び事業提携情報
    Summary Valeritas Inc (Valeritas) is a medical technology company that develops and commercializes treatment solutions for diabetes. The company’s product includes V-Go insulin delivery device a wearable basal-bolus insulin delivery solution for patients with Type 2 diabetes. It also provides V-Go l …
  • The Dow Chemical Co (DOW)-石油・ガス分野：企業M&A・提携分析
    Summary The Dow Chemical Company (Dow) is a diversified chemical company. Its businesses encompass specialty chemicals, advanced materials, agrosciences and plastics. The company manufactures and supplies products used primarily as raw materials in the manufacture of customer products and services. …
  • Toronto Hydro Corporation：電力：M&Aディール及び事業提携情報
    Summary Toronto Hydro Corporation (Toronto Hydro) is a municipal electricity distribution utility. It holds businesses in electricity distribution and street lighting and expressway lighting services in Toronto. The company owns and operates electricity distribution system, which delivers electricit …
  • Rottneros AB (RROS)：企業の財務・戦略的SWOT分析
    Rottneros AB (RROS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • PricewaterhouseCoopers LLP (UK)：企業の戦略的SWOT分析
    PricewaterhouseCoopers LLP (UK) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • SteadyMed Therapeutics Inc：医療機器：M&Aディール及び事業提携情報
    Summary SteadyMed Therapeutics Inc (SteadyMed), a subsidiary of SteadyMed Ltd is a pharmaceutical company that develops and commercializes therapeutic product candidates. The company provides patchpump, a customizable, pre-filled, and pre-programmed disposable parenteral delivery platform for large …
  • Seventh Sense Biosystems Inc-医療機器分野：企業M&A・提携分析
    Summary Seventh Sense Biosystems Inc (Seventh Sense) is a medical device company that develops and markets blood collection devices. The company’s products comprise testing devices, TAP devices, sterile and microneedle arrays among others. It uses TAP Touch Activated Phlebotomy painless blood collec …
  • Link Healthcare Pty Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Link Healthcare Pty Ltd (LINK), a subsidiary of Clinigen Group Plc, is a healthcare solution provider that provides generic products. The company offers therapeutic products, prescription, OTC medicines and medical devices in various therapeutic areas. It offers products such as relistor, an …
  • Magnit：企業の戦略・SWOT・財務情報
    Magnit - Strategy, SWOT and Corporate Finance Report Summary Magnit - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Deutsche Postbank AG：企業の戦略・SWOT・財務情報
    Deutsche Postbank AG - Strategy, SWOT and Corporate Finance Report Summary Deutsche Postbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Collplant Biotechnologies Ltd (CLGN)：企業の製品パイプライン分析
    Summary Collplant Biotechnologies Ltd (CollPlant) is a regenerative medicine company that carries out the development and commercialization of tissue repair products. The company offers orthobiologics, wound care, and pipeline products. Its orthobiologics products include VergenixSTR and VergenixBVF …
  • Grid2020, Inc.：電力：M&Aディール及び事業提携情報
    Summary Grid2020, Inc. (Grid2020) is a provider of smart grid solutions. The company offers an integrated distribution transformer monitoring solutions under the brand Optanode. The Optanode product family consists of sensors and smart analytics software and provides information about the distributi …
  • Kuwait Petroleum International Ltd：石油・ガス：M&Aディール及び事業提携情報
    Summary Kuwait Petroleum International Ltd (KPI), a subsidiary of Kuwait Petroleum Corporation, is a downstream energy company. It carries out refining of crude oil, production and marketing of refined petroleum products. The company operates refinery in Milazzo, Italy, and has retail service statio …
  • MidAmerican Energy Co：電力：M&Aディール及び事業提携情報
    Summary MidAmerican Energy Company (MidAmerican Energy), a subsidiary of Berkshire Hathaway Energy, is a regulated electric and natural gas utility company that carries out the generation, transmission and distribution and selling of electricity. The company also undertakes distribution, selling and …
  • Semiconductor Manufacturing International Corporation：企業のM&A・事業提携・投資動向
    Semiconductor Manufacturing International Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Semiconductor Manufacturing International Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes busin …
  • FibroStatin SL：製薬・医療：M&Aディール及び事業提携情報
    Summary FibroStatin SL (FibroStatin) is a drug development company that focuses on the development of treatment candidates for drug resistant lung cancer and idiopathic pulmonary fibrosis. The company’s pipeline products include T12/FST12 for NSCLC, GPBP-Mab/FSM26 for idiopathic pulmonary fibrosis a …
  • Loblaw Companies Limited：戦略・SWOT・企業財務分析
    Loblaw Companies Limited - Strategy, SWOT and Corporate Finance Report Summary Loblaw Companies Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Shinsegae Inc (004170)：企業の財務・戦略的SWOT分析
    Shinsegae Inc (004170) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Jubilant Life Sciences Ltd (JUBILANT)：製薬・医療：M&Aディール及び事業提携情報
    Summary Jubilant Life Sciences Ltd (Jubilant) is an integrated pharmaceutical and life sciences company that provides pharmaceuticals, life science ingredients and drug discovery solutions. The company’s product portfolio includes radiopharmaceuticals, allergy therapy products, active pharmaceutical …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆